公开(公告)号：WO2012166617A3

公开(公告)日：2014-05-08

申请号：PCT/US2012039628

申请日：2012-05-25

Applicant: CYTOCURE LLC ,  GEN HOSPITAL CORP ,  HAGGERTY TIMOTHY J ,  KURNICK JAMES T ,  DUNN IAN S

Inventor： HAGGERTY TIMOTHY J ,  KURNICK JAMES T ,  DUNN IAN S

IPC: A61K39/395 ,  A61K38/21 ,  A61P35/00

CPC classification number: A61K35/14 ,  A61K31/045 ,  A61K31/122 ,  A61K31/192 ,  A61K31/4178 ,  A61K31/495 ,  A61K31/4965 ,  A61K35/15 ,  A61K35/17 ,  A61K38/215 ,  A61K38/217 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/3053 ,  A61K2300/00

Abstract: The invention features methods, compositions, and kits for the administration of an HSP90 inhibitor, OBAA, flunarizine, aphidicolin, damnacanthal, dantrolene, or an analog thereof, alone, or in combination with, e.g., a TAA, an antigen-binding scaffold (e.g., an antibody, a soluble T cell receptor, or a chimeric receptor) specific for a TAA, a cell (e.g., a white blood cell that targets a cancer cell), and/or an IFN-&bgr; receptor agonist or an IFN-γ receptor agonist, for the treatment of cancer.

Abstract translation: 本发明的特征在于单独给予HSP90抑制剂，OBAA，氟桂灵，阿奇非丁，丹那卡他敏，丹曲林或其类似物的方法，组合物和试剂盒，或与例如TAA，抗原结合支架（ 例如特异于TAA，细胞（例如靶向癌细胞的白细胞）的抗体，可溶性T细胞受体或嵌合受体）和/或IFN-和bgr; 受体激动剂或IFN-γ受体激动剂，用于治疗癌症。

公开(公告)号：WO2004019886A3

公开(公告)日：2004-09-10

申请号：PCT/US0327125

申请日：2003-08-29

Applicant: CYTOCURE LLC ,  DURDA PAUL J ,  KURNICK JAMES T ,  DUNN IAN S

Inventor： DURDA PAUL J ,  KURNICK JAMES T ,  DUNN IAN S

IPC: A61B19/00 ,  A61K20060101 ,  A61K38/21 ,  A61K39/00 ,  A61K39/395 ,  C07K16/30 ,  G01N33/50

CPC classification number: C07K16/3053 ,  A61K35/15 ,  A61K38/215 ,  A61K39/0011 ,  A61K2039/55522 ,  G01N33/5011 ,  A61K2300/00

Abstract: The invention provides methods of modulating tumor antigen associated (TAA) expression, and methods of modulating TAA expression in order to treat a tumor. More particularly, the invention provides methods of increasing an immune response against tumor cell. Methods include administering to a subject with a tumor an amount of IFN-beta receptor agonist and tumor associated antigen (TAA) sufficient to increase an immune response against the tumor cell.

Abstract translation: 本发明提供调节肿瘤抗原相关（TAA）表达的方法以及调节TAA表达以治疗肿瘤的方法。 更具体地，本发明提供增加针对肿瘤细胞的免疫应答的方法。 方法包括向患者施用一定量的IFN-β受体激动剂和足以增加针对肿瘤细胞的免疫应答的肿瘤相关抗原（TAA）。

公开(公告)号：WO2012166617A2

公开(公告)日：2012-12-06

申请号：PCT/US2012/039628

申请日：2012-05-25

Applicant: CYTOCURE LLC ,  THE GENERAL HOSPITAL CORPORATION ,  HAGGERTY, Timothy, J. ,  KURNICK, James, T. ,  DUNN, Ian, S.

Inventor： HAGGERTY, Timothy, J. ,  KURNICK, James, T. ,  DUNN, Ian, S.

IPC: A61K39/395

CPC classification number: A61K35/14 ,  A61K31/045 ,  A61K31/122 ,  A61K31/192 ,  A61K31/4178 ,  A61K31/495 ,  A61K31/4965 ,  A61K35/15 ,  A61K35/17 ,  A61K38/215 ,  A61K38/217 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/3053 ,  A61K2300/00

Abstract: The invention features methods, compositions, and kits for the administration of an HSP90 inhibitor, OBAA, flunarizine, aphidicolin, damnacanthal, dantrolene, or an analog thereof, alone, or in combination with, e.g., a TAA, an antigen-binding scaffold (e.g., an antibody, a soluble T cell receptor, or a chimeric receptor) specific for a TAA, a cell (e.g., a white blood cell that targets a cancer cell), and/or an IFN-β receptor agonist or an IFN-γ receptor agonist, for the treatment of cancer.

Abstract translation: 本发明的特征在于单独给予HSP90抑制剂，OBAA，氟桂灵，阿奇非丁，丹那卡他敏，丹曲林或其类似物的方法，组合物和试剂盒，或与例如TAA，抗原结合支架（ 例如针对TAA，细胞（例如靶向癌细胞的白血细胞）和/或IFN-β受体激动剂或IFN-β受体激动剂特异性的抗体，可溶性T细胞受体或嵌合受体， ？ 受体激动剂，用于治疗癌症。

公开(公告)号：WO2004019886A2

公开(公告)日：2004-03-11

申请号：PCT/US2003/027125

申请日：2003-08-29

Applicant: CYTOCURE LLC ,  DURDA, Paul, J. ,  KURNICK, James, T. ,  DUNN, Ian, S.

Inventor： DURDA, Paul, J. ,  KURNICK, James, T. ,  DUNN, Ian, S.

IPC: A61K

CPC classification number: C07K16/3053 ,  A61K35/15 ,  A61K38/215 ,  A61K39/0011 ,  A61K2039/55522 ,  G01N33/5011 ,  A61K2300/00

Abstract: The invention provides methods of modulating tumor antigen associated (TAA) expression, and methods of modulating TAA expression in order to treat a tumor. More particularly, the invention provides methods of increasing an immune response against tumor cell. Methods include administering to a subject with a tumor an amount of IFN-β receptor agonist and tumor associated antigen (TAA) sufficient to increase an immune response against the tumor cell.

Abstract translation: 本发明提供了调节肿瘤抗原相关（TAA）表达的方法以及调节TAA表达以治疗肿瘤的方法。 更具体地说，本发明提供了增加针对肿瘤细胞的免疫应答的方法。 方法包括向患有肿瘤的受试者施用足以增加针对肿瘤细胞的免疫应答的量的IFN-β受体激动剂和肿瘤相关抗原（TAA）。